Revance Therapeutics, Inc.
7555 Gateway Boulevard
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance uses a unique proprietary, stabilizing excipient peptide technology to create novel, differentiated therapies. The company’s lead compound, DaxibotulinumtoxinA for Injection (RT002), is in clinical development for a broad range of aesthetic and therapeutic indications, including glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. The company is advancing a robust pipeline of injectable and topical formulations of DaxibotulinumtoxinA. More information on Revance may be found at www.revance.com.
143 articles with Revance Therapeutics, Inc.
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
Nolet will serve as Chair of the Audit Committee
Beraud will also chair newly-formed Brand Strategy Committee
Revance Therapeutics, Inc. announced that the company will participate in the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019 Healthcare Conference in New York, NY.
Conference call and webcast today at 4:30 p.m. ET
Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET
Revance Therapeutics, Inc. announced a pivotal addition to its leadership team with the appointment of Taryn Conway as Vice President, Marketing, effective April 8, 2019.
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced podium and poster presentations of its SAKURA 3 Phase 3 open-label, long-term safety study of DaxibotulinumtoxinA for Injection (DAXI) for the treatment of glabellar (frown) lines at the 17th Aesthetics & Anti-Aging Medical World Congress (AMWC).
Revance Therapeutics, Inc. announced that the Company will participate in the Needham Healthcare Conference in New York, NY.
Revance Therapeutics, Inc., a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, announced that the Company will participate in two upcoming investor conferences.
Revance Therapeutics, Inc. announced results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET
Gross Proceeds of Offering Total 115.0 Million
Revance Therapeutics, Inc. today announced the pricing of an underwritten public offering of 5,882,353 shares of its common stock at a price to the public of $17.00 per share.
Revance Therapeutics, Inc. today announced a proposed underwritten public offering in which it will issue and sell approximately $100 million of shares of its common stock.
Revance’s long-acting neuromodulator RT002, along with its unique proprietary peptide and formulation technology, will be featured in 11 podium and poster presentations at the TOXINS 2019 conference in Denmark
Completes Type B Pre-BLA meeting with U.S. FDA for glabellar lines indication and remains on track to submit application in first half of 2019
Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
In SAKURA 3, RT002 was well-tolerated across over 3,800 treatments in glabellar (frown) lines
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd